行情

BLUE

BLUE

bluebird bio
NASDAQ

实时行情|Nasdaq Last Sale

42.61
+0.10
+0.24%
盘后: 42.61 0 0.00% 16:13 04/02 EDT
开盘
42.09
昨收
42.51
最高
44.11
最低
41.49
成交量
54.21万
成交额
--
52周最高
163.43
52周最低
38.95
市值
23.70亿
市盈率(TTM)
-2.9791
分时
5日
1月
3月
1年
5年

分析师评级

22位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLUE价格均价为115.65,最高价位221.00,最低价为70.00。

EPS

BLUE 新闻

更多
  • Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
  • Business Wire · 2天前
  • What You Need To Know About The bluebird bio, Inc. (NASDAQ:BLUE) Analyst Downgrade Today
  • Simply Wall St. · 2天前
  • Celgene CVR holders near finish line with bb2121 filing in U.S.
  • Seeking Alpha - Article · 2天前
  • What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One
  • Investor's Business Daily · 2天前

所属板块

生物技术和医学研究
+2.93%
制药与医学研究
+2.56%

热门股票

代码
价格
涨跌幅

BLUE 简况

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
展开

微牛提供bluebird bio Inc(NASDAQ-BLUE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLUE股票新闻,以帮助您做出投资决策。